Gene Expression Profile Analysis of Type 2 Diabetic Mouse Liver

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Zhang, Fang ^a   Xu, Xiang ^a   Zhang, Yi ^a   Zhou, Ben ^a   He, Zhishui ^a   Zhai, Qiwei ^a  

^a Chinese Academy of Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; APOLIPOPROTEIN A1; BONE MORPHOGENETIC PROTEIN 4; CYTOCHROME P450 1A1; CYTOCHROME P450 26A1; CYTOCHROME P450 2A5; CYTOCHROME P450 2B10; CYTOCHROME P450 2B13; CYTOCHROME P450 2C29; CYTOCHROME P450 2C39; CYTOCHROME P450 2C50; CYTOCHROME P450 2C55; CYTOCHROME P450 3A; CYTOCHROME P450 3A11; CYTOCHROME P450 3A13; CYTOCHROME P450 3A16; CYTOCHROME P450 3A44; CYTOCHROME P450 3A59; DIACYLGLYCEROL ACYLTRANSFERASE; GLUTATHIONE TRANSFERASE A3; GLUTATHIONE TRANSFERASE T1; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; HIGH DENSITY LIPOPROTEIN; JANUS KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RETINOID X RECEPTOR; SERINE PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG; FATTY ACID; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCOGENOLYSIS; GLYCOLYSIS; HEPATITIS; HIGH THROUGHPUT SEQUENCING; LIVER; LIVER CANCER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; RISK FACTOR; TRANSGENIC MOUSE;

ANIMALS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUCOSE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; LIVER; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RISK FACTORS;

EID: 84874561591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057766     Document Type: Article

References (69)

1. Yach D, Stuckler D, Brownell KD, (2006) Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 12: 62-66.
2. Yang G, Pan C, Lu J, (2010) Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus. Int J Impot Res 22: 310-317.
3. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42: 579-589.
4. DeFronzo RA (2004) Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 88: 787-835, ix.
5. Bouche C, Serdy S, Kahn CR, Goldfine AB, (2004) The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 25: 807-830.
6. Agius L, (2010) Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors. Mini Rev Med Chem 10: 1175-1187.
7. van Poelje PD, Dang Q, Erion MD, (2007) Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of type 2 diabetes. Curr Opin Drug Discov Devel 10: 430-437.
8. McCormack JG, Westergaard N, Kristiansen M, Brand CL, Lau J, (2001) Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr Pharm Des 7: 1451-1474.
9. Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, et al. (2006) The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55: 1-12.
10. Lefebvre P, Chinetti G, Fruchart JC, Staels B, (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116: 571-580.
11. Stoffel M, Duncan SA, (1997) The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A 94: 13209-13214.
12. Lewis GF, Carpentier A, Adeli K, Giacca A, (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: 201-229.
13. McGarry JD, (2002) Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51: 7-18.
14. Postic C, Girard J, (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838.
15. van Lunteren E, Moyer M, (2009) Gene expression profiling in the type 1 diabetes rat diaphragm. PLoS One 4: e7832.
16. Dhahbi JM, Mote PL, Cao SX, Spindler SR, (2003) Hepatic gene expression profiling of streptozotocin-induced diabetes. Diabetes Technol Ther 5: 411-420.
17. Suh YH, Kim Y, Bang JH, Choi KS, Lee JW, et al. (2005) Analysis of gene expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic Zucker diabetic fatty rats. J Mol Endocrinol 34: 299-315.
18. Zhou H, Saito S, Piao G, Liu ZP, Wang J, et al. (2011) Network screening of Goto-Kakizaki rat liver microarray data during diabetic progression. BMC Syst Biol 5 (Suppl 1): S16.
19. Kim S, Sohn I, Ahn JI, Lee KH, Lee YS, (2004) Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene 340: 99-109.
20. Lan H, Rabaglia ME, Stoehr JP, Nadler ST, Schueler KL, et al. (2003) Gene expression profiles of nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes 52: 688-700.
21. Hoen PA, Ariyurek Y, Thygesen HH, Vreugdenhil E, Vossen RH, et al. (2008) Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms. Nucleic Acids Res 36: e141.
22. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y, (2008) RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 18: 1509-1517.
23. Blencowe BJ, Ahmad S, Lee LJ, (2009) Current-generation high-throughput sequencing: deepening insights into mammalian transcriptomes. Genes Dev 23: 1379-1386.
24. Hess B, Boiteux A, (1971) Oscillatory phenomena in biochemistry. Annu Rev Biochem 40: 237-258.
25. Nordlie RC, Foster JD, Lange AJ, (1999) Regulation of glucose production by the liver. Annu Rev Nutr 19: 379-406.
26. Bradbury MW, (2006) Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 290: G194-198.
27. Kersten S, Desvergne B, Wahli W, (2000) Roles of PPARs in health and disease. Nature 405: 421-424.
28. Koves TR, Li P, An J, Akimoto T, Slentz D, et al. (2005) Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem 280: 33588-33598.
29. Randle PJ, (1998) Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14: 263-283.
30. Wellen KE, Hotamisligil GS, (2005) Inflammation, stress, and diabetes. J Clin Invest 115: 1111-1119.
31. Dandona P, Aljada A, Bandyopadhyay A, (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25: 4-7.
32. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-1685.
33. Keller MP, Choi Y, Wang P, Davis DB, Rabaglia ME, et al. (2008) A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res 18: 706-716.
34. Marzban L, Rahimian R, Brownsey RW, McNeill JH, (2002) Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo. Endocrinology 143: 4636-4645.
35. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ, (2003) VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 301: 513-517.
36. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.
37. Abu-Elheiga L, Oh W, Kordari P, Wakil SJ, (2003) Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proc Natl Acad Sci U S A 100: 10207-10212.
38. Foley JE, (1992) Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 15: 773-784.
39. Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, et al. (2007) Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 13: 1193-1202.
40. Postic C, Girard J, (2008) The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 34: 643-648.
41. Pilkis SJ, Granner DK, (1992) Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54: 885-909.
42. DeFronzo RA, Bonadonna RC, Ferrannini E, (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15: 318-368.
43. Samuel VT, Shulman GI, (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148: 852-871.
44. Dunaway GA, Leung GL, Thrasher JR, Cooper MD, (1978) Turnover of hepatic phosphofructokinase in normal and diabetic rats. Role of insulin and peptide stabilizing factor. J Biol Chem 253: 7460-7463.
45. Wu C, Kang JE, Peng LJ, Li H, Khan SA, et al. (2005) Enhancing hepatic glycolysis reduces obesity: differential effects on lipogenesis depend on site of glycolytic modulation. Cell Metab 2: 131-140.
46. Wu C, Okar DA, Newgard CB, Lange AJ, (2001) Overexpression of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase in mouse liver lowers blood glucose by suppressing hepatic glucose production. J Clin Invest 107: 91-98.
47. O'Doherty RM, Lehman DL, Telemaque-Potts S, Newgard CB, (1999) Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48: 2022-2027.
48. Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, et al. (1995) Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 41: 966-978.
49. Olefsky JM, Glass CK, (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219-246.
50. Shoelson SE, Lee J, Goldfine AB, (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793-1801.
51. Fernandez-Real JM, Pickup JC, (2008) Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 19: 10-16.
52. Demir M, Serin E, Gokturk S, Ozturk NA, Kulaksizoglu S, et al. (2008) The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. Eur J Gastroenterol Hepatol 20: 668-673.
53. Sangiorgio L, Attardo T, Gangemi R, Rubino C, Barone M, et al. (2000) Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res Clin Pract 48: 147-151.
54. Soverini V, Persico M, Bugianesi E, Forlani G, Salamone F, et al. (2011) HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. Acta Diabetol 48: 337-343.
55. Knolle PA, Gerken G, (2000) Local control of the immune response in the liver. Immunol Rev 174: 21-34.
56. Liaskou E, Wilson DV, Oo YH, (2012) Innate immune cells in liver inflammation. Mediators Inflamm 2012: 949157.
57. Lanthier N, Molendi-Coste O, Horsmans Y, van Rooijen N, Cani PD, et al. (2010) Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol 298: G107-116.
58. Neyrinck AM, Cani PD, Dewulf EM, De Backer F, Bindels LB, et al. (2009) Critical role of Kupffer cells in the management of diet-induced diabetes and obesity. Biochem Biophys Res Commun 385: 351-356.
59. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60: 207-221.
60. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ, (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159: 1160-1167.
61. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R, (2009) Diabetes and cancer. Endocr Relat Cancer 16: 1103-1123.
62. Zhang F, Xu X, Zhou B, He Z, Zhai Q, (2011) Gene expression profile change and associated physiological and pathological effects in mouse liver induced by fasting and refeeding. PLoS One 6: e27553.
63. Audic S, Claverie JM, (1997) The significance of digital gene expression profiles. Genome Res 7: 986-995.
64. RDC T (2010) R: A Language and Environment for Statistical Computing. Vienna Austria R Foundation for Statistical Computing.
65. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
66. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
67. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354-357.
68. Osborne JD, Flatow J, Holko M, Lin SM, Kibbe WA, et al. (2009) Annotating the human genome with Disease Ontology. BMC Genomics 10 (Suppl 1): S6.
69. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504.